1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394-424.
2. Weigelt B, Peterse JL, van't Veer LJ: Breast cancer metastasis: markers and models. Nature Reviews Cancer 2005; 5:591-602.
3. Ohtsubo K, Marth JD: Glycosylation in cellular mechanisms of health and disease. Cell 2006; 126:855-867.
4. Mehta A, Herrera H, Block T: Glycosylation and liver cancer. Adv Cancer Res 2015; 126:257-279.
5. Miyoshi E, Moriwaki K, Nakagawa T: Biological Function of Fucosylation in Cancer Biology. J Biochem 2008; 143:725-729.
6. Holst S, Wuhrer M, Rombouts Y: Glycosylation characteristics of colorectal cancer. Adv Cancer Res 2015; 126:203-256.
7. Takahashi S, Sugiyama T, Shimomura M, Kamada Y, Fujita K, Nonomura N, Miyoshi E, Nakano M: Site-specific and linkage analyses of fucosylated N-glycans on haptoglobin in sera of patients with various types of cancer: possible implication for the differential diagnosis of cancer. Glycoconj J 2016; 33:471-482.
8. Kizuka Y, Taniguchi N: Enzymes for N-Glycan Branching and Their Genetic and Nongenetic Regulation in Cancer. Biomolecules 2016; 6.
9. Becker DJ, Lowe JB: Fucose: biosynthesis and biological function in mammals. Glycobiology 2003; 13:41r-53r.
10. Miyoshi E, Noda K, Yamaguchi Y, Inoue S, Ikeda Y, Wang W, Ko JH, Uozumi N, Li W, Taniguchi N: The alpha1-6-fucosyltransferase gene and its biological significance. Biochim Biophys Acta 1999; 1473:9-20.
11. Tu C-F, Wu M-Y, Lin Y-C, Kannagi R, Yang R-B: FUT8 promotes breast cancer cell invasiveness by remodeling TGF-β receptor core fucosylation. Breast Cancer Res 2017; 19:111.
12. Wang X, Gu J, Ihara H, Miyoshi E, Honke K, Taniguchi N: Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem 2006; 281:2572-2577.
13. Zhao Y, Itoh S, Wang X, Isaji T, Miyoshi E, Kariya Y, Miyazaki K, Kawasaki N, Taniguchi N, Gu J: Deletion of core fucosylation on alpha3beta1 integrin down-regulates its functions. J Biol Chem 2006; 281:38343-38350.
14. Agrawal P, Fontanals-Cirera B, Sokolova E, Jacob S, Vaiana CA, Argibay D, Davalos V, McDermott M, Nayak S, Darvishian F et al: A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis. Cancer Cell 2017; 31:804-819.e807.
15. Chen CY, Jan YH, Juan YH, Yang CJ, Huang MS, Yu CJ, Yang PC, Hsiao M, Hsu TL, Wong CH: Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proc Natl Acad Sci U S A 2013; 110:630-635.
16. Höti N, Lih T-S, Pan J, Zhou Y, Yang G, Deng A, Chen L, Dong M, Yang R-B, Tu C-F et al: A Comprehensive Analysis of FUT8 Overexpressing Prostate Cancer Cells Reveals the Role of EGFR in Castration Resistance. Cancers (Basel) 2020; 12:468.
17. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F: Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013; 8:2281-2308.
18. Krämer A, Green J, Pollard J, Jr., Tugendreich S: Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 2014; 30:523-530.
19. Pedemonte N, Galietta LJ: Structure and function of TMEM16 proteins (anoctamins). Physiol Rev 2014; 94:419-459.
20. Gonzalez A, Valeiras M, Sidransky E, Tayebi N: Lysosomal integral membrane protein-2: a new player in lysosome-related pathology. Mol Genet Metab 2014; 111:84-91.
21. Junk DJ, Bryson BL, Jackson MW: HiJAK’d Signaling; the STAT3 Paradox in Senescence and Cancer Progression. Cancers (Basel) 2014; 6:741-755.
22. Ara T, DeClerck YA: Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010; 46:1223-1231.
23. Dethlefsen C, Højfeldt G, Hojman P: The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 2013; 138:657-664.
24. Jones SA, Scheller J, Rose-John S: Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. The Journal of Clinical Investigation 2011; 121:3375-3383.
25. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, Hall BM: Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009; 28:2940-2947.
26. West NR, Murray JI, Watson PH: Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene 2014; 33:1485-1494.
27. Rolt A, Nair A, Cox LS: Optimisation of a screening platform for determining IL-6 inflammatory signalling in the senescence-associated secretory phenotype (SASP). Biogerontology 2019; 20:359-371.
28. Ganguly KK, Pal S, Moulik S, Chatterjee A: Integrins and metastasis. Cell Adhesion & Migration 2013; 7:251-261.
29. Hamidi H, Ivaska J: Every step of the way: integrins in cancer progression and metastasis. Nature reviews Cancer 2018; 18:533-548.
30. Zutter MM, Krigman HR, Santoro SA: Altered integrin expression in adenocarcinoma of the breast. Analysis by in situ hybridization. Am J Pathol 1993; 142:1439-1448.
31. Zutter MM, Mazoujian G, Santoro SA: Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am J Pathol 1990; 137:863-870.
32. Li W, Ishihara K, Yokota T, Nakagawa T, Koyama N, Jin J, Mizuno-Horikawa Y, Wang X, Miyoshi E, Taniguchi N et al: Reduced α4β1 Integrin/VCAM-1 Interactions Lead to Impaired Pre-B Cell Repopulation in Alpha 1,6-Fucosyltransferase Deficient Mice. Glycobiology 2007; 18:114-124.
33. von Schlippe M, Marshall JF, Perry P, Stone M, Zhu AJ, Hart IR: Functional interaction between E-cadherin and alphav-containing integrins in carcinoma cells. J Cell Sci 2000; 113:425.
34. Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP: Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 1999; 59:5307-5314.
35. Lu X, Lu D, Scully M, Kakkar V: The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. Perspect Medicin Chem 2008; 2:57-73.
36. Rathinam R, Alahari SK: Important role of integrins in the cancer biology. Cancer Metastasis Rev 2010; 29:223-237.
37. Sawhney RS, Liu W, Brattain MG: A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via Fak signaling. J Cell Physiol 2009; 219:152-161.
38. Wang Y, Fukuda T, Isaji T, Lu J, Gu W, Lee H-h, Ohkubo Y, Kamada Y, Taniguchi N, Miyoshi E et al: Loss of α1,6-fucosyltransferase suppressed liver regeneration: implication of core fucose in the regulation of growth factor receptor-mediated cellular signaling. Sci Rep 2015; 5:8264.
39. Desgrosellier JS, Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nature reviews Cancer 2010; 10:9-22.
40. Paccez JD, Vogelsang M, Parker MI, Zerbini LF: The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer 2014; 134:1024-1033.
41. Li J, Jia L, Ma Z-H, Ma Q-H, Yang X-H, Zhao Y-F: Axl glycosylation mediates tumor cell proliferation, invasion and lymphatic metastasis in murine hepatocellular carcinoma. World J Gastroenterol 2012; 18:5369-5376.
42. Ellis LM: The role of neuropilins in cancer. Mol Cancer Ther 2006; 5:1099.
43. Naik A, Al-Zeheimi N, Bakheit CS, Al Riyami M, Al Jarrah A, Al Moundhri MS, Al Habsi Z, Basheer M, Adham SA: Neuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study. Sci Rep 2017; 7:3301.
44. Awan B, Turkov D, Schumacher C, Jacobo A, McEnerney A, Ramsey A, Xu G, Park D, Kalomoiris S, Yao W et al: FGF2 Induces Migration of Human Bone Marrow Stromal Cells by Increasing Core Fucosylations on N-Glycans of Integrins. Stem cell reports 2018; 11:325-333.
45. Wang X, Inoue S, Gu J, Miyoshi E, Noda K, Li W, Mizuno-Horikawa Y, Nakano M, Asahi M, Takahashi M et al: Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci U S A 2005; 102:15791-15796.